Accretion PharmaceuticalsNSE:ACCPL +4.96%18 Pretax Margin % is 14.54% as of Mar. 2026, which is 0% below its 10-year median of 14.60. GuruFocus rates NSE:ACCPL with a GF Score™ of 18/100. The stock has 6 warning signs investors should review. Among 953 Drug Manufacturers companies, Accretion Pharmaceuticals ranks better than 69.05% on this metric.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Accretion Pharmaceuticals Pretax Margin % Related Terms
Accretion Pharmaceuticals Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ACCPL vs LLY, JNJ, ABBV: Pretax Margin % Comparison
For the Drug Manufacturers - General subindustry, Accretion Pharmaceuticals's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Accretion Pharmaceuticals Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Accretion Pharmaceuticals's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Accretion Pharmaceuticals's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accretion Pharmaceuticals (NSE:ACCPL) has a Pretax Margin % of 14.54% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Accretion Pharmaceuticals and its competitors. This is near median its historical median of 14.60. Over the past decade, Accretion Pharmaceuticals' Pretax Margin % has ranged from 0.47 to 17.11. According to the industry distribution chart, Accretion Pharmaceuticals ranks #295 out of 953 companies in the Drug Manufacturers industry, placing it in the top 31%.
Is Accretion Pharmaceuticals' Pretax Margin % too high?
Accretion Pharmaceuticals' current Pretax Margin % of 14.54% is near median its 10-year median of 14.60. Over the past 10 years, this metric has ranged from a low of 0.47 to a high of 17.11. The Drug Manufacturers industry median Pretax Margin % is 7.30. Accretion Pharmaceuticals' value of 14.54% is 99.2% above this industry median. Based on the distribution chart, Accretion Pharmaceuticals ranks #295 out of 953 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Accretion Pharmaceuticals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Accretion Pharmaceuticals' Pretax Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Accretion Pharmaceuticals ranks #295 out of 953 companies for Pretax Margin %. This puts Accretion Pharmaceuticals in the upper half of its industry. The industry median Pretax Margin % is 7.30. Accretion Pharmaceuticals' value of 14.54% is 99.2% above this benchmark. Historically, Accretion Pharmaceuticals' own Pretax Margin % has ranged from 0.47 to 17.11 over the past decade. While the company's 10-year median is 14.60 vs. the industry median of 7.30, Accretion Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.30, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Accretion Pharmaceuticals's current Pretax Margin % of 14.54% is 99.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Accretion Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Accretion Pharmaceuticals's current Pretax Margin % is 14.54%, which is near median its own 10-year median of 14.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accretion Pharmaceuticals stock overvalued right now?
Accretion Pharmaceuticals (NSE:ACCPL) has a current Pretax Margin % of 14.54%. The current Pretax Margin % is 14.54%, which is near median its 10-year median of 14.60 and 99.2% above the Drug Manufacturers industry median of 7.30. Accretion Pharmaceuticals' overall GF Score™ is 18/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Accretion Pharmaceuticals (NSE:ACCPL), the current Pretax Margin % is 14.54% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Accretion Pharmaceuticals Ltd is engaged in the manufacturing of Medicinal & Pharmaceutical Products. The company manufactures tablets, oral liquid, capsule, cream, ointment, mouthwash, dusting powder, gel, ear drops, lotion, shampoo, powder, syrup, among others.
18GF Score
Get the complete analysis for NSE:ACCPL
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ACCPL has been successfully added to your 